0.75
+0.0398(+5.58%)
Currency In USD
Address
10240 Sorrento Valley Road
San Diego, CA 92121
United States of America
Phone
858 731 8389
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Sanjay S. Shukla M.D., M.S. | President, Chief Executive Officer & Director | 838,762 | 1972 |
| Ms. Nancy E. Denyes Krueger J.D. | General Counsel & Corporate Secretary | 568,865 | 1968 |
| Ms. Jill M. Broadfoot CPA | Chief Financial Officer | 585,723 | 1962 |
| Ms. Dalia R. Rayes M.B.A. | Head of Commercial, Global Efzofitimod Franchise | 0 | N/A |
| Mr. Peter Villiger | Vice President of Corporate Development | 0 | N/A |
| Dr. Leslie Nangle Ph.D. | Vice President of Research | 0 | N/A |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications | 0 | N/A |
| Ms. Danielle Campbell | Vice President of Human Resource | 0 | N/A |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.